Tatiana Thula

Tatiana Thula is a healthcare professional associated with Novo Nordisk, where she serves as the coordinator for diabetes and rare diseases. In her role, she focuses on providing innovative and safe therapies for diabetes management and obesity treatment. Thula has recently been in the news for clarifying that the pricing strategy for medications like Ozempic, which has seen a reduction in the US, is specific to that market and does not extend to Guatemala or the region.